Shots: The positive CHMP opinion of Zerbaxa (3gm) is based on P-III ASPECT-NP study assessing Zerbaxa in patients with hospital-acquired pneumonia including ventilator-associated pneumonia. The EC will review CHMP’s opinion […]readmore
Tags : ZERBAXA
Shots: The approval is based on P-III ASPECT-NP study results assessing Zerbaxa (3gm, IV every 8hrs.) vs meropenem (1gm, IV, every 8hrs.) in 726 patients with HABP/VABP on mechanical ventilation […]readmore
Shots: ASPECT-NP study (N=726) assessing ZERBAXA 3g IV (ceftolozane & tazobactam) vs. Meropenem 1g IV every eight hrs. for 8 to 14 days/ 14 days for Pseudomonas aeruginosa infection ASPECT-NP […]readmore